Name in SEC filings: Ocugen, Inc.
Source: ORION, orionbiotechai.com/company/OCGN, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/OCGN
OCU400 · Topline/data readout · 1Q 2027
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout1Q 2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: $279,200,000 · as of · SEC filing
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-03)
NDA/BLA submissionby the second quarter of 2027
Stage: —
Public float: $279,200,000 · as of · SEC filing
We expect to begin a rolling BLA submission in the third quarter of 2026 and plan to complete the BLA submission by the second quarter of 2027.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readoutsecond quarter of 2027
Stage: Not stated
Public float: $279,200,000 · as of · SEC filing
Topline results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| OCU410STClinical results | second quarter of 2027“Topline results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OCU400Clinical results | 1Q 2027“Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| OCU400Submission | by the second quarter of 2027“We expect to begin a rolling BLA submission in the third quarter of 2026 and plan to complete the BLA submission by the second quarter of 2027.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| OCU400Submission | by the second quarter of 2027“The Company plans to initiate the rolling BLA submission for OCU400 in the third quarter of 2026 and complete the BLA submission by the second quarter of 2027.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| OCU410STClinical results | second quarter of 2027“Topline results are expected in the second quarter of 2027 with the BLA submission by mid-2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for OCGN. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See OCGN in the calendar · Review labels and methodology